US 11827900
Engineered target specific nucleases
granted A61KA61K38/00
Quick answer
US patent 11827900 (Engineered target specific nucleases) held by Sangamo Therapeutics, Inc. expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Sangamo Therapeutics, Inc.
- Grant date
- Tue Nov 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K38/00